Goldman Says FDA Response to Energy Drink Safety Review 'Encouraging' for Monster
Commenting on the action in Monster Beverage this afternoon, Goldman Sachs analyst Judy Hong called the FDA's response to the energy drink safety issue "generally benign." Hong believes this should be encouraging for Monster. The analyst believes the most likely outcome related to Durbin's energy drink review will be strong labeling, something which is unlikely to have a material impact on Monster.
Latest Ratings for MNST
|Dec 2014||RBC Capital||Downgrades||Top Pick||Outperform|
|Nov 2014||Longbow Research||Assumes||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.